Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
combination therapy
Pharma
Pfizer eyes earlier Talzenna use after ph. 3 prostate cancer win
If approved, Talzenna would be the first PARP inhibitor to enter the HRR-mutant metastatic hormone-sensitive prostate cancer setting.
Angus Liu
Mar 19, 2026 6:45am
Merck's Welireg combos deliver 1-2 punch to kidney cancer
Feb 28, 2026 10:00am
Padcev-Keytruda combo wins in MIBC amid evolving landscape
Feb 27, 2026 10:00am
Jazz touts Ziihera as HER2 agent of choice in stomach cancer
Jan 6, 2026 3:25pm
Incyte to seek FDA approval for Monjuvi in front-line DLBCL
Jan 5, 2026 10:40am
Keytruda, Padcev keep winning streak in bladder cancer
Dec 17, 2025 9:53am
